Publisher
Springer Science and Business Media LLC
Reference43 articles.
1. Rome BN, Lee CC, Kesselheim AS. Market exclusivity length for drugs with new generic or biosimilar competition, 2012–2018. Clin Pharmacol Ther. 2021;109:367–71. https://doi.org/10.1002/cpt.1983.
2. Xu F, Carlson SA, Liu Y, Greenlund KJ. Prevalence of inflammatory bowel disease among Medicare fee-for-service beneficiaries — United States, 2001–2018. MMWR Morb Mortal Wkly Rep. 2021;70:698–701.
3. Kahn-Boesel O, Cautha S, Ufere NN, Ananthakrishnan AN, Kochar B. A narrative review of financial burden, distress, and toxicity of inflammatory bowel diseases in the United States. Am J Gastroenterol. 2023;118:1545–53. https://doi.org/10.14309/ajg.0000000000002345. A recent study highlighting the significant financial burdens and toxicity associated with inflammatory bowel disease.
4. Biosimilars overview for health care professionals. [Internet]. U.S. Food & Drug Administration. Updated March 1, 2023. Available from: https://www.fda.gov/drugs/biosimilars/overview-health-care-professionals
5. Mulcahy AW, Hlavka JP, Case SR. Biosimilar cost savings in the United States: Initial experience and future potential. Rand Health Q. 2018;7:3.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献